Title: development of novel anticancer agent to potentiate sensitivity to anti-estrogen therapy

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400040C
Awardee
Awarding agency
Obligated
$1,454,426

Award facts

Opportunity
  • N44CO4700413 Solicitation number
  • Amendment No. 4 Award Notice · Posted Jan 10, 2014
Contract value 100% obligated
$1,454,425.92 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Columbia, MD 21045, USA
Research
SBIR Program Phase II Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00003 -$24,126
Supplemental Agreement for work within scope 2 $0
Supplemental Agreement for work within scope 1 $0
Original award $1,478,552

Quick answers

Who was awarded contract HHSN261201400040C?

HHSN261201400040C was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2014.

How much is contract HHSN261201400040C worth?

The government has obligated $1,454,426 on HHSN261201400040C.

Was contract HHSN261201400040C competed?

The extent of competition for HHSN261201400040C was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award